Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity
Zevra Therapeutics Analyst Ratings
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $22
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Zevra Therapeutics (ZVRA)
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $22
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $19
William Blair Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating
William Blair Keeps Their Buy Rating on Zevra Therapeutics (ZVRA)
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $18
Buy Rating on Zevra Therapeutics Backed by Strong Financials and Promising Product Launches
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $19
Zevra Therapeutics Analyst Ratings
Zevra Therapeutics Analyst Ratings
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $18
Buy Rating Affirmed for Zevra Therapeutics Amid Strong AdCom Support and High Market Potential
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $18
Zevra Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $15 Price Target
Buy Rating for Zevra Therapeutics Amid Anticipated Approval of Arimoclomol for Rare Neurodegenerative Disease